TRANSFORMING U.S. INVENTION INTO INNOVATION

Transcription

1 TRANSFORMING U.S. INVENTION INTO INNOVATION

2 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by Allied Minds plc (the "Company"). The information in the Presentation is not intended to form the basis of any contract. By attending (whether in person or by telephone) or reading the Presentation, you agree to the conditions set out below. THIS PRESENTATION IS NOT A PROSPECTUS. The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of the Company, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract whatsoever relating to any securities. Allied-Bristol Life Sciences, LLC (ABLS) The Presentation is provided for general information only and does not purport to contain all the information that may be required to evaluate the Company. The information in the Presentation is provided as at the date of the Presentation (unless stated otherwise) and is subject to updating, completion, revision and further verification. No reliance may be placed for any purpose whatsoever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions. To the extent permitted by law or regulation, no undertaking, representation or warranty or other assurance, express or implied, is made or given by or on behalf of the Company, or any of its parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of their respective directors, officers, partners, employees, agents, affiliates, representatives or advisors, or any other person, as to the accuracy, completeness or fairness of the information or opinions contained in the Presentation. Save in the case of fraud, no responsibility or liability is accepted by any such person for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred, however arising, directly or indirectly, from any use of, as a result of the reliance on, or otherwise in connection with, the Presentation. In addition, no duty of care or otherwise is owed by any such person to recipients of the Presentation or any other person in relation to the Presentation. Nothing in the Presentation is, or should be relied on as, a promise or representation as to the future. The Presentation includes certain statements, estimates, opinions and projections provided by the Company in relation to strategies, plans, intentions, expectations, objectives and anticipated future performance of the Company and its subsidiaries. By their nature, such statements, estimates, opinions and projections involve risk and uncertainty since they are based on various assumptions made by the Company concerning anticipated results which may or may not prove to be correct and because they may relate to events and depend on circumstances that may or may not occur in the future and may be beyond the Company s ability to control or predict. No representations or warranties of any kind are made by any person as to the accuracy of such statements, estimates, opinions or projections, or that any of the events expressed or implied in any such statements, estimates or projections will actually occur. The Company is not under any obligation, and expressly disclaims any intention, to update or revise any such statements, estimates, opinions or projections following the date of this Presentation. No statement in the Presentation is intended as a profit forecast or a profit estimate. Certain industry and market data contained in this Presentation has come from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry and market data contained in this Presentation comes from the Company's own internknowledge al research and estimates based on the and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice 2

3 Introduction Company Novel Joint Venture between Allied Minds (AM) and Bristol-Myers Squibb (BMS) to foster the development of new drug candidates based Allied-Bristol Life Sciences, LLC academic institutions (ABLS) upon transformational discoveries from leading Mission Develop novel therapeutics in areas of high unmet medical need which are aligned with BMS disease strategy 3

4 ABLS Joint Venture - Structure AM and BMS Joint Venture (JV) Attractive Return Potential JV: AM (~80%) & BMS (<~20%) Subsidiaries ABLS Joint Venture pre-clinical - Structure phase ABLS ABLS I ABLS II ABLS n Pre-negotiated exits at completion of early, lower risk Exit terms with BMS Upfront payment as multiple of investment Additional milestone payments also as multiple of investment Royalty based on product sales Aim to launch ~10 subsidiaries focused on developing lead series around promising targets 4

5 Bristol-Myers Squibb Overview ~US$110B Market Cap (NYSE: BMY) Mission: To discover, develop and deliver innovative medicines Bristol-Myers that help patients Squibb prevail Company over serious diseases. at a Ranked Best Drug Company Glance of 2013 by Forbes Magazine Ranked #1 Drug Company in R&D Performance in 2014* ~25,000 employees Portfolio of 98 products in 57 markets 2014 Total Revenues of $15.9B (R&D budget of ~$4-5B) Deep drug discovery and development expertise in-house and through Biocon-BMS R&D Center ( BBRC ) in India * Sector & Sovereign Health 5

6 Leadership Team: ABLS and BMS Satish Jindal, PhD; CEO Former VP, BMS; VP/Site Head, Schering-Plough (now Merck) Also, CEO/Founder, NeoGenesis; Co- Founder/President, Verastem & Vedantra Donna See, MBA; MPH, Vice President, Allied Minds Former Director, Licensing, Columbia University focused on life sciences Also, Founding Director, Columbia-Coulter Translational Research Carl D. Decicco, PhD Sr VP and Head Discovery, BMS Catherine Strader, PhD; Advisor 30+ years pharma R&D experience; 50+ compounds through development Exec leadership positions at Merck and (EVP) Schering- Plough John G. Houston Sr VP, Disease Sciences and Biologics, BMS Omar Amirana, MD; Senior Vice President, Allied Minds Former Partner, Oxford Bioscience Partners VP Business Development, St. Jude Medical Art Bertelsen, PhD VP, Research Collaborations, BMS Ben Askew, PhD; Advisor VP, Research SciFluor Former VP Research, EMD Serono; Executive positions at Merck and Amgen 6

7 Leadership Team: Synergy Partners Network Partnership with Synergy Partners Network for access to industry experts who have brought dozens of drugs from discovery to market Trusted ABLS partner for technical and project leadership Leadership Team: Synergy Partners Network Jim MacDonald Drug Development Catherine Strader Marvin Bayne Drug Discovery Genomics/Biomarkers Bob Bishop Oncology Joy Cavagnaro Toxicology Shelley Ching Toxicology Greg Davis CMC Ashit Ganguly Chemistry Jay Gibbs Oncology Mike Graziano Cardiometabolic Bill Greenlee Chemistry Stacy Hammonds Project Management Russ Hensel Bioanalytical Bill Kramer Clinical PK/PD Sandy Mills Chemistry Rick Morrison DMPK John Piwinski Chemistry Scott Reines Clinical Bill Schinzer CMC Eve Slater Clinical/Regulatory John Stubbs Bioanalytical Ron White DMPK 7

8 BBRC: BMS R&D Site in India Secured Access to BBRC provides ABLS Broad, Low Cost, High Quality R&D Capabilities BBRC (Biocon-Bristol-Myers Squibb Research & Development Center) is a collaboration between BMS and Syngene International, a Biocon-group company. 200,000 s.f. state of the art facility in Bangalore, India. Expertise in drug discovery and early development. BBRC: BMS R&D Site in India ~575 scientists and support staff. Fully integrated R&D capabilities: Medical chemistry, Synthetic Chemistry, in vitro Biology, in vivo Biology, PK, Tox, APIs, Pharmaceutical development, etc. ~ 30% of U.S. costs, with comparable or better output Drives ~ programs annually Consistent delivery of Early Compound Nominations (ECNs), contributing to BMS pipeline Expertise in Fibrosis, Oncology, immune sciences well aligned with BMS R&D strategy and ABLS mandate 8

9 Company at a Glance Founded 2014 Cambridge, Massachusetts USA Company at a Glance ABLS I formed to execute on IP related to prostate oncology from an Ivy League institution ABLS II formed to execute on IP related to fibrotic diseases from a second Ivy League institution Allied Minds ownership ~80% 9

10 Areas of Interest for ABLS Aligned with BMS Oncology; Immuno-Oncology Fibrosis Areas of Interest for ABLS Aligned with BMS Immunology Cardiovascular/Heart Failure Genetically Defined Diseases Virology Exposure to potential multi-billon dollar global opportunities 10

11 ABLS Investment Process Opportunity ID US Universities & National Labs Direct Outreach Formal RFP Process Due Diligence Review Principal Investigator Expert Technical Assessment: ABLS/BMS/Synergy Commercial Potential ABLS Investment Process Feasibility Phase ABLS BOD & Technical Advisor Approval Launch Subsidiary ID Lead Compound incl. Initial Testing Up to $1M Mutual Agreement on ECN Milestones Optimization Phase Complete ECN (Early Candidate Nomination) through Pre-clinical Activities ~ $10M-$15M Exit: Subsidiary Sale to BMS 11

12 Strong Pipeline of Opportunities >30 Institutions queried Strong Pipeline of Opportunities >500 Opportunities evaluated Filtered with BMS 20 under due diligence Two term sheet discussions on-going Sourced 637 Triaged 458 Evaluate 161 Expanding pipeline 20 12

13 Expected Timeline Project Launch 2 3 Subsidiaries Subsidiaries Subsidiaries Expected Timeline Feasibility Assessment 2 3 Subsidiaries 3 4 Subsidiaries 2 3 Subsidiaries Compound Optimization 2 3 Subsidiaries 3 4 Subsidiaries 2 3 Subsidiaries 13

14 Investment Highlights Large Pharma relies more on external innovation models Universities are skilled in discovery and validation of targets ABLS bridges the gap between University research and clinical candidates in cost effective, reduced risk model ABLS is a Win-Win for BMS and AM Investment Highlights Access to breakthroughs via AM university/fed. lab network Motivated, pre-identified acquirer Focused on multi-billion dollar blockbusters Exits with potentially outsized returns (up-fronts, milestones & royalties) Model which can scale 14

15 TRANSFORMING U.S. INVENTION INTO INNOVATION